Overview: ICA TestIntroduction: The ICA Test detects islet cell antibodies to diagnose type 1 diabetes, causing high blood sugar or fatigue, helping guide treatment. Affecting 1 in 300 children with diabetes, type 1 diabetes poses diagnostic challenges due to autoimmune onset. Following 2023 American Diabetes Association (ADA) guidelines, it uses immunofluorescence for high sensitivity, supporting immunology screening. This test is vital for diagnosis, therapy planning, and improving outcomes in endocrinology.
Other Names: Islet Cell Antibody Test, Type 1 Diabetes Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Autoantibody testing began in the 1970s with research by Bottazzo, who identified islet cell antibodies. Immunofluorescence advancements in the 1990s by Bio-Rad improved detection, surpassing earlier indirect methods.
Purpose: Detects islet cell antibodies to diagnose type 1 diabetes, guides insulin therapy, and evaluates patients with high blood sugar, aiming to manage disease.
Test Parameters: Islet cell antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of diabetes symptoms.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document high blood sugar or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., ketoacidosis), and sample collection risks.
Procedural Considerations: Uses immunofluorescence to measure antibodies, requiring labs with microscopes. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive antibodies confirm type 1 diabetes, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Normal levels may require other antibody tests.
Specialist Consultation: Consult an endocrinologist for interpretation.
Additional Supporting Tests: C-peptide, HbA1c, or autoantibody panel to confirm diagnosis.
Test Limitations: Specific to islet cells; correlation with symptoms needed. False positives possible with other autoimmune diseases.
References: ADA Guidelines, 2023; Diabetologia, Bottazzo GF, 2022.
